Akebia Therapeutics, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001517022-26-000039
- Form type
- 10-Q
- CIK
- 0001517022
- Primary document
- https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Akebia Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $53.5M | - | - |
| Cost Of Revenue | $12.3M | - | - |
| Operating Income | $-4.7M | - | - |
| Net Income | $-9.1M | - | - |
| Eps Basic | -0.03 | - | - |
| Eps Diluted | -0.03 | - | - |
| Cash And Equivalents | $162.6M | - | - |
| Total Assets | $362.5M | - | - |
| Total Liabilities | $335.1M | - | - |
| Shareholders Equity | $27.4M | - | - |
| Operating Cash Flow | $-21.2M | - | - |
| Capital Expenditures | $62,000 | - | - |